company background image
IGMS

IGM Biosciences NasdaqGS:IGMS Stock Report

Last Price

US$22.30

Market Cap

US$955.0m

7D

-12.2%

1Y

25.6%

Updated

09 Feb, 2023

Data

Company Financials +

IGM Biosciences, Inc.

NasdaqGS:IGMS Stock Report

Mkt Cap: US$955.0m

IGMS Stock Overview

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.

IGMS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

IGM Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IGM Biosciences
Historical stock prices
Current Share PriceUS$22.30
52 Week HighUS$35.98
52 Week LowUS$12.67
Beta-0.19
1 Month Change18.11%
3 Month Change-12.14%
1 Year Change25.56%
3 Year Change-50.81%
5 Year Changen/a
Change since IPO-8.23%

Recent News & Updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05
Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05
Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23
IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09
We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07
Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

Feb 08
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

IGM Biosciences reports quick assets and provides business updates

Jan 13

Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares

Dec 18
Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares

IGM Bio prices upsized $200M public offering

Dec 09

IGM Biosciences proposes public offering

Dec 07

IGM Biosciences (IGMS) Investor Presentation - Slideshow

Nov 20

Shareholder Returns

IGMSUS BiotechsUS Market
7D-12.2%-1.8%-1.8%
1Y25.6%1.9%-10.9%

Return vs Industry: IGMS exceeded the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: IGMS exceeded the US Market which returned -10.8% over the past year.

Price Volatility

Is IGMS's price volatile compared to industry and market?
IGMS volatility
IGMS Average Weekly Movement16.2%
Biotechs Industry Average Movement11.9%
Market Average Movement6.6%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: IGMS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: IGMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1993242Fred Schwarzerhttps://igmbio.com

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company’s lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.

IGM Biosciences, Inc. Fundamentals Summary

How do IGM Biosciences's earnings and revenue compare to its market cap?
IGMS fundamental statistics
Market CapUS$955.03m
Earnings (TTM)-US$219.17m
Revenue (TTM)US$697.00k

1,370x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IGMS income statement (TTM)
RevenueUS$697.00k
Cost of RevenueUS$46.42m
Gross Profit-US$45.72m
Other ExpensesUS$173.45m
Earnings-US$219.17m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.12
Gross Margin-6,559.25%
Net Profit Margin-31,444.48%
Debt/Equity Ratio0%

How did IGMS perform over the long term?

See historical performance and comparison